These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 38974234

  • 1. Early discontinuation of immune checkpoint inhibitor therapy prior to disease progression in patients with metastatic non-small cell lung cancer: a survival analysis.
    McKinley BJ, Pai TS, Wolf EB, Li S, Correia GSC, Zhao Y, Manochakian R, Lou Y.
    Front Oncol; 2024; 14():1417175. PubMed ID: 38974234
    [Abstract] [Full Text] [Related]

  • 2. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors.
    Cook S, Samuel V, Meyers DE, Stukalin I, Litt I, Sangha R, Morris DG, Heng DYC, Pabani A, Dean M, Navani V.
    JAMA Netw Open; 2024 Jan 02; 7(1):e2352302. PubMed ID: 38236598
    [Abstract] [Full Text] [Related]

  • 3. Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events.
    Nizam A, Rader RK, Tzeng A, Wei W, Sheng IY, Martin A, Wee CE, Gilligan TD, Gupta S, Ornstein MC.
    Clin Genitourin Cancer; 2024 Apr 02; 22(2):368-379. PubMed ID: 38245437
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events.
    Fujisaki T, Watanabe S, Ota T, Kushiro K, Sato Y, Takahashi M, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Hokari S, Kondo R, Miyabayashi T, Abe T, Miura S, Tanaka H, Okajima M, Terada M, Matsumoto N, Ishida T, Iwashima A, Sato K, Yoshizawa H, Aoki N, Hayashi M, Ohshima Y, Koya T, Kikuchi T.
    Front Oncol; 2021 Apr 02; 11():704475. PubMed ID: 34631533
    [Abstract] [Full Text] [Related]

  • 6. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
    Kim H, Kim DW, Kim M, Lee Y, Ahn HK, Cho JH, Kim IH, Lee YG, Shin SH, Park SE, Jung J, Kang EJ, Ahn MJ.
    Cancer; 2022 Feb 15; 128(4):778-787. PubMed ID: 34705268
    [Abstract] [Full Text] [Related]

  • 7. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT, Su CT, Hu M, Taylor JMG, Daignault-Newton S, Kellezi O, Dahl MN, Shah MA, Erickson S, Lora J, Hamasha R, Ali A, Yancey S, Kiros L, Balicki HM, Winfield DC, Green MD, Alva AS.
    Urol Oncol; 2021 Jul 15; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [Abstract] [Full Text] [Related]

  • 8. Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.
    Torasawa M, Yoshida T, Takeyasu Y, Shimoda Y, Tateishi A, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Takahashi K, Ohe Y.
    Cancer Med; 2023 Jun 15; 12(11):12388-12401. PubMed ID: 37062059
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
    Tian T, Yu M, Yu Y, Wang K, Tian P, Luo Z, Ding Z, Wang Y, Gong Y, Zhu J, Zou B, Sio TT, Alves A, Liu Y, Huang M, Lu Y.
    Transl Lung Cancer Res; 2022 Jun 15; 11(6):1027-1037. PubMed ID: 35832458
    [Abstract] [Full Text] [Related]

  • 11. Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy.
    Sayer MR, Mambetsariev I, Lu KH, Wong CW, Duche A, Beuttler R, Fricke J, Pharoan R, Arvanitis L, Eftekhari Z, Amini A, Koczywas M, Massarelli E, Roosan MR, Salgia R.
    Front Oncol; 2023 Jun 15; 13():1064169. PubMed ID: 36860308
    [Abstract] [Full Text] [Related]

  • 12. Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.
    Van Buren I, Madison C, Kohn A, Berry E, Kulkarni RP, Thompson RF.
    JAMA Netw Open; 2023 Oct 02; 6(10):e2340695. PubMed ID: 37906189
    [Abstract] [Full Text] [Related]

  • 13. Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study.
    Bilger G, Girard N, Doubre H, Levra MG, Giroux-Leprieur E, Giraud F, Decroisette C, Carton M, Massiani MA.
    Cancer Immunol Immunother; 2022 Jul 02; 71(7):1719-1731. PubMed ID: 34821950
    [Abstract] [Full Text] [Related]

  • 14. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA, Ettinger DS, Hann CL, Brahmer JR, Ricciuti B, Owen D, Toi Y, Walker P, Otterson GA, Patel SH, Sugawara S, Naidoo J.
    JAMA Oncol; 2020 Dec 01; 6(12):1952-1956. PubMed ID: 33119034
    [Abstract] [Full Text] [Related]

  • 15. Discontinuation of Immune Checkpoint Inhibitor due to irAEs in NSCLC Patients With EGFR Mutation.
    Okauchi S, Miyazaki K, Shiozawa T, Yamada H, Satoh H, Hizawa N.
    Cancer Diagn Progn; 2023 Dec 01; 3(2):244-250. PubMed ID: 36875301
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Association Between the Severity of Immune-related Adverse Events and the Prognosis in Patients With Non-small Cell Lung Cancer Receiving Treatment With Immune Checkpoint Inhibitors.
    Inomata M, Matsumoto M, Hayashi K, Seto Z, Hirai T, Tokui K, Taka C, Okazawa S, Kambara K, Imanishi S, Miwa T, Hayashi R, Matsui S, Tobe K.
    Anticancer Res; 2023 Jul 01; 43(7):3241-3246. PubMed ID: 37351972
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.